RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects of RO4929097 before surgery in treating
patients with pancreatic cancer. RO4929097 may stop the growth of tumor cells by blocking
some enzymes needed for cell growth. Giving RO4929097 before surgery may make the tumor
smaller and reduce the amount of normal tissue that needs to be removed.